Items where authors include "Flanagan, L"

Export as [feed] Atom [feed] RSS
Number of items: 13.

Article

Hinsley, S, Walker, K, Sherratt, D et al. (13 more authors) (2020) The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials, 21 (1). 826. 826-.

Coleman, R, Brown, J, Rathbone, E et al. (9 more authors) (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials, 21. 89. ISSN 1745-6215

Buckley, HL orcid.org/0000-0002-9829-5817, Collinson, FJ, Ainsworth, G et al. (15 more authors) (2019) PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19. ARTN: 1102. ISSN 1471-2407

Brown, SR, Hall, A, Buckley, H orcid.org/0000-0002-9829-5817 et al. (9 more authors) (2019) Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer, 19 (1). ARTN: 582. ISSN 1471-2407

Popat, R, Brown, SR, Flanagan, L et al. (10 more authors) (2019) Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). British Journal of Haematology, 185 (3). pp. 573-578. ISSN 0007-1048

Brown, SR, Sherratt, D, Booth, G et al. (4 more authors) (2017) Experiences of Establishing an Academic Early Phase Clinical Trials Unit. Clinical Trials, 14 (4). pp. 349-356. ISSN 1740-7745

Wadsley, J, Gregory, R, Flux, G et al. (6 more authors) (2017) SELIMETRY- A Multicentre I-131 Dosimetry Trial: A Clinical Perspective. British Journal of Radiology, 90 (1073). 20160637. ISSN 0007-1285

Popat, R, Brown, SR, Flanagan, L et al. (9 more authors) (2016) Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. The Lancet Haematology, 3 (12). e572-e580. ISSN 2352-3026

Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688, Ballesteros, M et al. (11 more authors) (2016) The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. BMC hematology, 16. p. 14. ISSN 2052-1839

Schey, S, Brown, SR, Tillotson, A-L et al. (13 more authors) (2015) Bendamustine, thalidomide and dexamethasone combinationtherapy for relapsed/refractory myeloma patients: results ofthe MUKone randomized dose selection trial. British Journal of Haematology, 170 (3). pp. 336-348. ISSN 0007-1048

Conference or Workshop Item

Garg, M, Hall, A, Jenner, M et al. (10 more authors) (2019) A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results. In: 61st ASH (American Society of Hematology) Annual Meeting & Exposition, 07-10 Dec 2019, Orlando, FL.

Proceedings Paper

Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.

Yong, KL, Brown, S, Hinsley, S orcid.org/0000-0001-6903-4688 et al. (8 more authors) (2015) Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen. In: Blood. 57th ASH Annual Meeting and Exposition, 05-08 Dec 2015, Orlando, FL, USA. American Society of Hematology .

This list was generated on Sat Mar 23 16:44:06 2024 GMT.